**Gelidium amansii** extract ameliorates obesity by down-regulating adipogenic transcription factors in diet-induced obese mice

Ji-Hye Kang1, Hyun-Ah Lee1, Hak-Ju Kim3 and Ji-Sook Han1,2,§

1Department of Food Science and Nutrition, Pusan National University, 2, Busandaehak-ro 63beon-gil, Geumjeong-ju, Busan 46241, Korea
2Research Institute of Ecology for the Elderly, Pusan National University, Busan 46241, Korea
3Seojin Biotech Co., Ltd., Yongin, Gyeonggi 17015, Korea

**BACKGROUND/OBJECTIVES:** In this study, we investigated whether *Gelidium amansii* extract (GAE) ameliorates obesity in diet-induced obese (DIO) mice.

**MATERIALS/METHODS:** The mice were maintained on a high-fat diet (HD) for 5 weeks to generate the DIO mouse model. And then mice fed HD plus 0.5% (GAE1), 1% (GAE2) or 2% (GAE3) for 8 weeks.

**RESULTS:** After the experimental period, GAE-supplemented groups were significantly lower than the HD group in body weight gain and liver weight. GAE supplemented groups were significantly lower than the HD group in both epididymal and mesenteric adipose tissue mass. The plasma leptin level was significantly higher in the HD group than in GAE-supplemented groups. The expression levels of adipogenic proteins such as fatty acid synthase, sterol regulatory element-binding protein-1c, peroxisome proliferator-activated receptor γ, and CCAAT/enhancer binding protein α in the GAE supplemented groups were significantly decreased compared to those of HD+CLA group. On the contrary, the expression levels of hormone-sensitive lipase decreased than those in HD group, respectively. In addition, the expression levels of HD+GAE2 and HD+GAE3 groups are significantly decreased compared to those of HD+CLA group. The leptin level of HD+GAE3 group was significantly lower than that of the HD+conjugated linoleic acid (CLA) group. In contrast, plasma adiponectin level of the HD group was significantly lower than those of HD+GAE2 and HD+GAE3 groups. The expression levels of adipogenic proteins such as fatty acid synthase, sterol regulatory element-binding protein-1c, peroxisome proliferator-activated receptor γ, and CCAAT/enhancer binding protein α in the GAE supplemented groups were significantly decreased than those in HD group, respectively. In addition, the expression levels of HD+GAE2 and HD+GAE3 groups are significantly decreased compared to those of HD+CLA group. On the contrary, the expression levels of hormone-sensitive lipase decreased than those in HD group, respectively. In addition, the expression levels of HD+GAE2 and HD+GAE3 groups are significantly decreased compared to those of HD+CLA group. The leptin level of HD+GAE3 group was significantly lower than that of the HD+conjugated linoleic acid (CLA) group.

**CONCLUSIONS:** These results suggested that GAE supplementation stimulated the expressions of lipid metabolic factors and reduced weight gain in HD-fed C57BL/6J obese mice.

Nutrition Research and Practice 2017;11(1):17-24; https://doi.org/10.4162/nrp.2017.11.1.17; pISSN 1976-1457 eISSN 2005-6168

**Keywords:** Adipogenesis, obesity, mice, genes, lipolysis

**INTRODUCTION**

Obesity is not defined by a single factor, rather it is a complex condition with multiple factors including hypertension, cardiovascular disease, insulin resistance, dyslipidemia, inflammation, and fatty liver [1,2]. Lipid accumulation induces the process of adipogenesis (the programmed differentiation of pre-adipocytes), which is involved in a number of stages related to obesity. Controlling adipogenesis is a potential strategy for obesity prevention because adipocyte differentiation plays a key role in fat mass growth [3,4]. The master adipogenic transcription regulators are CCAAT/enhancer binding protein α (C/EBP α) and peroxisome proliferator-activated receptor γ (PPARγ) [5]. These factors modulate adipogenesis-related gene expression and lipid storage in adipocytes [6]. Sterol regulatory element-binding protein (SREBP-1) also plays a role by upregulating many lipogenic genes, such as fatty acid synthase (FAS). On the contrary, hormone-sensitive lipase (HSL) [7] is the major enzymes regulating the process of lipolysis. Thus, there are many studies aimed at ameliorating obesity by focusing on reducing pre-adipocyte differentiation and proliferation, inhibiting lipogenesis, and inducing lipolysis [8].

Obesity results from a disorder of energy balance in terms of energy intake and energy expenditure [9]. To date, many different approaches have been suggested to control obesity, including drugs to suppress appetite, induce weight loss, or inhibit nutrient absorption [10]. Currently available therapeutic agent is orlistat [11]. However, orlistat causes serious adverse effects such as insomnia, asthenia, constipation, emesis, headache, and stomachache [12]. Thus, natural compounds that may be beneficial in reducing obesity have been investigated as alternatives [13].

This research was a part of the project titled “Development of an Individual Case-Authorized Functional new Biomaterial from Marine organism resources, 20133300911”, funded by the Ministry of Oceans and Fisheries, Korea.

©2017 The Korean Nutrition Society and the Korean Society of Community Nutrition

http://e-nrp.org

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Seaweed is rich in polyphenols, carotenoids, vitamins, phycobilins, and sulfated polysaccharides, many of which are known to have beneficial effects on human health [14]. *Gelidium amansii*, a well-known red alga, has been consumed since ancient times. Several studies have reported that *G. amansii* possesses anti-oxidative, immunomodulatory, anti-tumor, and cytotoxic effects resulting from the activity of phenolic compounds in its extract [15-17]. The study was also reported that *G. amansii* extract showed the inhibitory effect of weight gain in mice fed a high-fat diet added with *G. amansii* extract for 12 weeks [18]. However, there is not any study on the effect of weight loss of *G. amansii* extract in obese mice that fed only a high fat diet for a few weeks. Therefore, in this study, we investigated the effects of *G. amansii* extract on body weight gain, fat mass, plasma and hepatic lipid profiles, adipokine secretion, and expression of lipid metabolic factors in obese C57BL/6J mice.

**MATERIALS AND METHODS**

**Preparation of Gelidium amansii extract**

Samples of *G. amansii* were collected in Jeju Island, Korea from May to June 2014. The plant samples were washed three times to remove salt and sand, after which they were dried at room temperature and ground into powder. The powder was extracted with 80% ethanol for 24 h at 40°C. The resulting *G. amansii* extract (GAE) was concentrated in a rotary vacuum evaporator (40°C) and freeze-dried into powder form for use in animal experiments. The yield of GAE was 5.6 %. The GAE was analyzed to have a total polyphenolic content of 0.26 ± 0.08 mg/mL and a total flavonoid content of 1.55 ± 0.16 mg/mL.

**Animals and diets**

Male, 5-week-old C57BL/6J mice (n = 48) were purchased from Jung-Ang Lab Animal Inc. (Seoul, Korea). The mice were housed in a temperature-controlled room (24°C) with a 12 h light/dark cycle. After one week of adaptation, eight mice were fed normal diet (ND) and forty mice were fed a high-fat diet (HD, providing 60 kcal% fat; Jung-Ang Lab Animal Inc.) for 5 weeks to induce obesity. Eight mice of ND supplemented group continued to be fed the normal diet and then others divided into 5 groups (n = 8) that were fed a diet of HD, HD plus 0.5, 1.0, and 2.0 g GAE/100 g diet (HD+GAE1, HD+GAE2, and HD+GAE3, respectively), and HD plus 0.75 g conjugated linoleic acid (CLA, Novarex Co., Cheongju, Chungcheongbukdo, Korea)/100 g diet (HD+CLA) for 8 weeks. During the experimental period, animals had free access to water and food, and their body weight and food intake were measured weekly. At the end of the experimental period, the mice were sacrificed with ether after fasting for 12 h, and blood samples were taken from the inferior vena cava for assessment of plasma lipid, leptin, and adiponectin levels. Thereafter, the livers, kidneys, epididymal, and mesenteric adipose tissues were collected, rinsed, weighed, and stored at -80°C. The animal handling and care procedures used in this study were in accordance with current international laws and policies (PNU Guide for the Care and Use of Laboratory Animals; PNU-20150905).

**Plasma lipid, leptin and adiponectin levels**

Plasma levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were determined using commercial assay kits (Asan Pharm. Seoul, Korea) according to the manufacturer's instructions, while low-density lipoprotein cholesterol (LDL-C) levels were calculated using the Friedewald formula: LDL-C = TC - HDL-C - (TG/5) [19].

Also, Plasma free fatty acid (FFA) was determined using commercial assay kits (NEFA kit, Wako, Japan). Plasma leptin and adiponectin levels were measured using a mouse/rat leptin quantikine enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA) and a mouse/rat high-molecular-weight adiponectin ELISA kit (Shibayagi Co. Ltd, Gunma, Japan), respectively.

**Assay for hepatic lipids**

Hepatic lipids were extracted using a procedure described by Folch et al. [20], and hepatic cholesterol and triglyceride concentrations were analyzed using the enzymatic kits used for the plasma analyses.

**Western blot analysis**

Epididymal adipose tissue and liver homogenates in lysis buffer were centrifuged at 14,000 × g (4°C, 15 min), and the protein concentrations of the resulting supernatants were measured using a protein assay kit (Bio-Rad, Hercules, CA, USA). Protein samples (30 μg) were separated on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels. Separated proteins were transferred to nitrocellulose membranes that were blocked with 5% skim milk in Tris-buffered saline (0.1% Tween-20) for 1 h at room temperature. Blocked membranes were incubated overnight with primary antibodies against FAS, SREBP-1c, PPARγ, C/EBPα, HSL, and phospho-AMPKα (p-AMPK) (Cell Signaling Technology, Beverly, MA, USA) at 4°C. The membranes were then washed and incubated with secondary antibodies for 1 h at room temperature, after which each antigen-antibody complex was visualized using ECL Western blotting detection reagents and detected by chemiluminescence using a LAS-1000 plus analyzer (Fujifilm, Tokyo, Japan). Band densities were determined using an image analyzer (Multi Gauge V3.1; Fujifilm, Tokyo, Japan) and were normalized to β-actin levels.

**Data and statistical analyses**

Data are reported as mean ± standard deviation (SD) and statistical analyses were carried out using SAS software (SAS Ins-1ttute, Inc., Cary, NC, USA). Differences among groups were evaluated by one-way analysis of variance (ANOVA) followed by Duncan's multiple range tests. Differences of P < 0.05 were considered statistically significant.

**RESULTS**

**Effects of GAE supplementation on body weight, food intake, and food efficiency ratio**

After inducing obesity with HD for five weeks, the body weight of HD-fed mice (29.07 ± 3.44 g) was significantly higher than that of ND-fed mice (24.70 ± 0.95 g) (Fig. 1). To determine
whether GAE supplementation for eight weeks has a regulatory effect on obesity, the body weights of the animals were measured (Table 1). Body weight gains of HD, HD+GAE1, HD+GAE2, HD+GAE3, and HD+CLA groups were 12.48 ± 2.42, 8.30 ± 2.90, 3.93 ± 1.44, 3.18 ± 1.79 and 4.35 ± 2.23 g for 8 weeks, respectively. The weight gains of GAE-supplemented groups were significantly lower than that in the HD group. In particular, the liver weights in the HD+GAE2 and HD+GAE3 groups were significantly lower than those in the HD+GAE1 and HD+CLA group (Table 2). In addition, epididymal adipose tissue of the HD, HD+GAE1, HD+GAE2, HD+GAE3, and HD+CLA groups were 2.04 ± 1.00, 1.86 ± 0.56, 1.28 ± 0.38, 1.30 ± 0.14 and 1.37 ± 0.15 g, respectively. Mesenteric adipose tissue mass of the HD, HD+GAE1, HD+GAE2, HD+GAE3, and HD+CLA groups were 0.94 ± 0.38, 0.93 ± 0.45, 0.67 ± 0.30, 0.67 ± 0.12 and 0.61 ± 0.22 g, respectively. HD+GAE2 and HD+GAE3 groups were significantly lower than HD group in both epididymal and mesenteric adipose tissue mass. Also, the adipose tissue masses of the HD+GAE2 and HD+GAE3 were similar to those of HD+CLA group.

**Effects of GAE supplementation on liver, kidney, and adipose tissue mass**

Liver weights of the of the HD, HD+GAE1, HD+GAE2, HD+GAE3, and HD+CLA groups were 1.35 ± 0.02, 1.16 ± 0.07, 0.96 ± 0.02, 0.95 ± 0.01 and 1.17 ± 0.03 g, respectively. The liver weights of GAE supplemented groups were significantly lower than that in the HD group. In particular, the liver weights in the HD+GAE2 and HD+GAE3 groups were significantly lower than those in the HD+GAE1 and HD+CLA group (Table 2). In addition, epididymal adipose tissue of the HD, HD+GAE1, HD+GAE2, HD+GAE3, and HD+CLA groups were 2.04 ± 1.00, 1.86 ± 0.56, 1.28 ± 0.38, 1.30 ± 0.14 and 1.37 ± 0.15 g, respectively. Mesenteric adipose tissue mass of the HD, HD+GAE1, HD+GAE2, HD+GAE3, and HD+CLA groups were 0.94 ± 0.38, 0.93 ± 0.45, 0.67 ± 0.30, 0.67 ± 0.12 and 0.61 ± 0.22 g, respectively. HD+GAE2 and HD+GAE3 groups were significantly lower than HD group in both epididymal and mesenteric adipose tissue mass. Also, the adipose tissue masses of the HD+GAE2 and HD+GAE3 were similar to those of HD+CLA group.

### Table 1. Effects of GAE supplementation on body weight gain, food intake, and food efficiency ratio

|                | ND  | HD  | HD+CLA | HD+GAE1 | HD+GAE2 | HD+GAE3 |
|----------------|-----|-----|--------|---------|---------|---------|
| Start body weight (g) | 24.70 ± 0.95 | 29.07 ± 3.44 | 29.20 ± 1.04 | 29.04 ± 2.23 | 29.28 ± 1.73 | 29.01 ± 1.30 |
| Final body weight (g)   | 28.60 ± 1.90 | 41.55 ± 1.87 | 33.55 ± 1.20 | 37.34 ± 2.67 | 33.21 ± 1.03 | 32.19 ± 1.16 |
| Weight gain (g/week)    | 3.90 ± 1.0 | 12.48 ± 2.4 | 4.35 ± 2.23 | 8.30 ± 2.90 | 3.93 ± 1.44 | 3.18 ± 1.79 |
| Food intake (g/day)     | 2.53 ± 0.22 | 2.45 ± 0.17 | 2.39 ± 0.29 | 2.49 ± 0.52 | 2.39 ± 0.26 | 2.33 ± 0.21 |
| FER<sub>4</sub>         | 2.75 ± 0.12 | 9.10 ± 0.42 | 3.25 ± 0.27 | 5.96 ± 0.24 | 2.84 ± 0.32 | 2.44 ± 0.37 |

1) Values represent the mean ± SD (n = 8).
2) a-dValues denoted by different letters are significantly different among groups (P < 0.05).
3) NS: not significant.
4) FER: Food efficiency ratio = [weight gain (g)] / [total food intake (g) × 100].

### Table 2. Effects of GAE supplementation on liver, kidney, and adipose tissue mass

| Tissue          | ND  | HD  | HD+CLA | HD+GAE1 | HD+GAE2 | HD+GAE3 |
|-----------------|-----|-----|--------|---------|---------|---------|
| Liver           | 0.96 ± 0.06 | 1.35 ± 0.02 | 1.17 ± 0.03 | 1.16 ± 0.07 | 0.96 ± 0.02 | 0.95 ± 0.01 |
| Kidney          | 0.32 ± 0.03 | 0.35 ± 0.02 | 0.35 ± 0.04 | 0.36 ± 0.03 | 0.36 ± 0.04 | 0.34 ± 0.03 |
| Epididymal AT<sup>4</sup> | 0.82 ± 0.12 | 2.04 ± 1.00 | 1.37 ± 0.15 | 1.86 ± 0.56 | 1.28 ± 0.38 | 1.30 ± 0.14 |
| Mesenteric AT<sup>4</sup> | 0.36 ± 0.08 | 0.94 ± 0.38 | 0.61 ± 0.22<sup>ab</sup> | 0.93 ± 0.45 | 0.67 ± 0.30<sup>ab</sup> | 0.67 ± 0.12<sup>ab</sup> |

1) Values represent the mean ± SD (n = 8).
2) a-dValues denoted by different letters are significantly different among groups (P < 0.05).
3) NS: not significant.
4) AT: adipose tissue.
20 GAE ameliorates obesity in diet-induced obese mice.

|                       | ND               | HD               | HD+CLA           | HD+GAE1          | HD+GAE2          | HD+GAE3          |
|-----------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| **Plasma** (mg/dL)    |                  |                  |                  |                  |                  |                  |
| Triglyceride          | 156.20 ± 6.03    | 232.57 ± 5.78    | 190.55 ± 6.83    | 205.50 ± 7.88    | 199.73 ± 10.71   | 187.55 ± 4.91    |
| Total cholesterol     | 200.58 ± 6.04    | 267.89 ± 3.06    | 242.29 ± 2.18    | 263.76 ± 3.36    | 249.79 ± 3.40    | 241.50 ± 2.52    |
| HDL-cholesterol       | 53.19 ± 3.38     | 31.90 ± 6.63     | 47.45 ± 3.53     | 39.08 ± 2.80     | 45.26 ± 2.37     | 47.22 ± 2.89     |
| LDL-cholesterol       | 116.15 ± 1.85    | 189.48 ± 4.38    | 156.72 ± 5.23    | 183.58 ± 4.76    | 164.58 ± 4.92    | 156.77 ± 3.82    |
| FFAa                  | 0.85 ± 0.18      | 1.22 ± 0.30      | 0.49 ± 0.11      | 0.95 ± 0.10      | 0.61 ± 0.14      | 0.61 ± 0.15      |

| **Hepatic** (mg/g tissue) |                  |                  |                  |                  |                  |                  |
| Triglyceride           | 13.45 ± 1.05     | 38.32 ± 2.14     | 33.21 ± 0.36     | 31.56 ± 0.99     | 22.06 ± 1.12     | 21.32 ± 0.87     |
| Total cholesterol      | 3.96 ± 1.10      | 15.32 ± 1.68     | 13.91 ± 2.26     | 14.17 ± 1.42     | 11.02 ± 2.12     | 9.87 ± 0.95      |

1) Values represent the mean ± SD (n = 8).
2) Values denoted by different letters are significantly different among groups (P < 0.05).
3) FFA: free fatty acid.

ND, normal diet-fed mice; HD, high-fat diet-fed mice; HD+CLA, high-fat diet plus CLA (0.75 g/100 g diet)-fed mice; HD+GAE1, high-fat diet plus GAE (0.5 g/100 g diet)-fed mice; HD+GAE2, high-fat diet plus GAE (1 g/100 g diet)-fed mice; HD+GAE3, high-fat diet plus GAE (2 g/100 g diet)-fed mice. Values represent the mean ± SD (n = 8).

Effects of GAE supplementation on plasma and hepatic lipid levels

The effects of GAE supplementation on plasma and hepatic lipid levels were also examined. Compared with the GAE-supplemented groups, the HD group exhibited higher levels of TG, TC, LDL-C, and FFA but lower level of HDL-C (Table 3). TG, TC, LDL-C, and FFA levels of HD+GAE2 were 199.73 ± 10.71, 249.79 ± 4.91, 214.50 ± 2.52, 241.50 ± 2.52 mg/dL, respectively. Those of HD+GAE3 were 187.55 ± 4.91, 241.50 ± 2.52, 156.77 ± 3.82, 187.55 ± 4.91 mg/dL, respectively. TG, TC, LDL-C, and FFA levels of HD+GAE2 and HD+GAE3 groups were significantly decreased compared with those of HD group which were 232.57 ± 5.78, 267.89 ± 3.06, 189.48 ± 4.38, and 1.22 ± 0.30 mg/dL, respectively. Furthermore, HDL-C levels of the HD, HD+GAE1, HD+GAE2, HD+GAE3, and HD+CLA groups were 31.90 ± 4.63, 39.08 ± 2.80, 45.26 ± 2.37, 47.22 ± 2.89 mg/dL, respectively. The level of HD+GAE3 was the highest among the GAE groups and was similar with HD+CLA group.

The hepatic TC and TG levels of HD-fed mice were significantly increased compared with those of mice fed with ND. On the other hand, hepatic TG and TC levels of HD+GAE2, HD+GAE3 groups were significantly lower than those of HD group and HD+CLA group. The TG level of HD, HD+GAE1, HD+GAE2, HD+GAE3, and HD+CLA groups were 38.32 ± 2.14, 31.56 ± 0.99, 22.06 ± 1.12, 21.32 ± 0.87 and 33.21 ± 0.36 mg/g tissue, respectively. TC levels of HD, HD+GAE1, HD+GAE2, HD+GAE3, and HD+CLA groups were 13.45 ± 1.05, 38.32 ± 2.14, 31.56 ± 0.99, 22.06 ± 1.12, 13.91 ± 2.26 mg/g tissue, respectively. The level of HD+GAE3 group was significantly the lowest among the groups.

Effects of GAE supplementation on plasma leptin and adiponectin levels

The plasma leptin level was significantly higher in the HD group (62.88 ± 1.49 ng/mL) than in both ND and GAE-supplemented groups (Fig. 2A). Among the GAE supplemented groups, the leptin level of HD+GAE3 group exhibited the lowest level. In addition, the plasma leptin level of the HD+GAE3 group (13.29 ± 0.58 ng/mL) was also significantly lower than that of the HD+CLA group (16.02 ± 0.92 ng/mL). In contrast, plasma adiponectin level of the HD group (5.99 ± 0.30 μg/mL) was significantly lower than those of HD+GAE2 (7.96 ± 0.19 μg/mL) and HD+GAE3 (8.08 ± 0.14 μg/mL) groups. Also, the levels of HD+GAE2 and HD+GAE3 group were significantly higher than that of the HD+CLA group (7.52 ± 0.38 ng/mL) (Fig. 2B).

Effects of GAE supplementation on FAS, SREBP-1c, PPARγ, C/EBPα, HSL, and pAMPK expression

The expression levels of SREBP-1c, PPARγ, C/EBPα, HSL, and pAMPK were significantly different among groups (P < 0.05).

Fig. 2. Effects of GAE supplementation on plasma leptin and adiponectin levels. ND, normal diet-fed mice; HD, high-fat diet-fed mice; HD+CLA, high-fat diet plus CLA (0.75 g/100 g diet-fed mice; HD+GAE1, high-fat diet plus GAE (0.5 g/100 g diet-fed mice; HD+GAE2, high-fat diet plus GAE (1 g/100 g diet-fed mice; HD+GAE3, high-fat diet plus GAE (2 g/100 g diet-fed mice; Values represent the mean ± SD (n = 8). a–f Values denoted by different letters are significantly different among groups (P < 0.05).
in the adipose tissue, and FAS and pAMPK in the liver were analyzed along with that of their genes to investigate effect of GAE on mice. The expression levels of FAS, SREBP-1c, PPARγ, and C/EBPα in the GAE supplemented groups were significantly decreased than those in HD group, respectively (Fig. 3A and 3B). Especially, the expression levels of the genes in the HD+GAE2 and HD+GAE3 groups were significantly decreased compared to those of HD+CLA group. Among the GAE supplemented groups, the levels of SREBP-1c, PPARγ, C/EBPα in HD+GAE3 group were significantly lower than those of HD+GAE1 and HD+GAE2 groups. The results showed that GAE supplementation significantly reduced the expression levels of the adipogenesis-related genes.

On the contrary, the expression levels of HSL and pAMPK, proteins associated with lipolysis, were significantly increased in the GAE supplemented groups compared to those in the HD group. HD+GAE3 group showed the highest expression levels of HSL and pAMPK, among the GAE supplemented groups.

DISCUSSION

This study is aimed at investigating the anti-obesity effects of GAE in diet-induced obesity (DIO) mice model. Obesity is caused by an energy imbalance between energy intake and expenditure [21]. Weight gain and FER in the all GAE supplemented groups were significantly lower than those in the HD group when measured after 13 weeks. These results are consistent with previous studies [18]. In previous study, G. amansii extract showed the inhibitory effect of weight gain in C57BL/6J mice fed a high-fat diet added with G. amansii extract for 12 weeks. These studies indicated that GAE supplementation suppressed the weight gain in both DIO model obese mice and C57BL/6J mice fed a high-fat diet. However, DIO model obese mice inhibited weight gains when they fed high fat diet added with 1% of G. amansii extract, whereas C57BL/6J mice inhibited weight gains when they fed high fat diet added with 3% of G. amansii extract. These results suggested that inhibition effects of weight gain may be appeared in lower concentration of G. amansii extract supplementation in obese mice such as DIO model mice than in that in C57BL/6J mice. The reduction of epididymal and mesenteric adipose tissue mass of the HD+GAE2 and HD+GAE3 groups are significantly lower than those of HD group. Also, the adipose tissue masses of the HD+GAE2 and HD+GAE3 were similar to those of HD+CLA group. The reduction of weight gain in GAE-supplemented groups might be due to reduced epididymal and mesenteric fat mass; it was previously reported that reduced body weight gain can be associated with reduced fat mass [22]. In addition, Seo et al. [23] reported that GAE inhibited lipid accumulation in 3T3-L1 adipocytes.

Plasma levels of TG, TC, and LDL-C, considered as the main risk factors for dyslipidemia, were related to accumulation of fat in the abdominal viscera [24] and cardiovascular diseases [25]. Plasma TG, TC and LDL-C levels were significantly lower in the GAE-supplemented groups than in the HD group, while
the opposite is true for HDL-C levels. Especially, HD+GAE3 group was the lowest among the GAE groups and was similar with HD+CLA group in TG, TC and LDL levels. Hepatic TG and TC levels exhibited similar tendencies to those in the plasma. HD+GAE2 and HD+GAE3 groups were significantly lower than HD and HD+CLA groups in hepatic TG and TC levels. TG is synthesized in the liver and released into the blood as very low-density lipoprotein (VLDL) before being transported to the adipose tissue [26]. GAE supplementation improved lipid profile levels in the plasma and liver, which may be associated with reduced body weight and adipose tissue weight. Bioactive compounds such as polyphenols and flavonoids possess antioxidant and cholesterol-lowering activities [27]. It was reported that seaweed extract containing polyphenols and flavonoids inhibited adipocyte differentiation and lipid accumulation [28]. The GAE used in this study contained 260 µg/mL of polyphenols and 1,550 µg/mL of flavonoids. Thus, it is possible that the effects of GAE on reducing adipose tissue weight and improving lipid profile levels in the plasma and liver originated from the actions of polyphenols and flavonoids contained in GAE.

Adipokines are proteins involved in cell signaling that are secreted by fat cells and have profound effects on obesity [29]. Leptin, a type of adipokine, is one of the main regulators of fat metabolism and is associated with triglyceride accumulation in adipocytes [30]. Leptin levels are positively correlated with weight gain. Moreover, leptin levels increase in response to high calorie and decrease proportionally to reduction in adipose tissue mass [31,32]. In this study, leptin levels significantly decreased in GAE supplemented groups compared with the HD group. The plasma leptin level of HD+GAE3 group was significantly lower than those of the HD+GAE1, HD+GAE2 and HD+CLA groups. These findings suggest that GAE may decrease leptin secretion by reducing adipose tissue weight. Adiponectin, another adipokine secreted by fat cells, is a protein hormone related to insulin sensitivity and fatty acid catabolism that induces the activation of AMPK [33]. Plasma adiponectin levels are known to have an inverse correlation with obesity, diabetes, and atherosclerosis [34]; adiponectin tends to be secreted more in healthy animals and less in obese animals [35]. In the current study, adiponectin levels in HD+GAE2 and HD+GAE3 mice were significantly higher than that of the HD group mice. Also, the levels of HD+GAE2 and HD+GAE3 group were higher than that of the HD+CLA group. Increase in adiponectin level is related to weight loss [36]. Thus, increase in the level of this protein in HD+GAE mice may be due to weight loss of the mice when their diet was supplemented with GAE. Taken together, the present findings suggest that GAE supplementation could lower adipose tissue weight and body weight, thereby regulating plasma adipokine levels in obese mice.

Lipogenic transcriptional genes including PPARγ, C/EBPα, and SREBP-1c have an important role in the lipid metabolism of adipocytes during adipogenesis [37]. A key transcription gene in adipocyte differentiation and lipid storage [38], PPARγ induces adipogenesis by binding to the C/EBPα promoter region that stimulates the expression of C/EBPα [39]. Both C/EBPα and PPARγ are critical transcriptional factors in adipocyte differentiation and promotion of lipid storage [40]. Another transcription factor that PPARγ interacts with is SREBP-1c, which induces the production of lipophilic molecules that increase the activity of PPARγ [41]. In addition, PPARγ and SREBP-1c play key roles in regulating the expression of FAS, the enzyme involved in the rate-limiting step of fatty acid synthesis [42]. In our study, the expressions of adipogenesis-related genes such as PPARγ, C/EBPα, SREBP-1c, and FAS were significantly decreased in the HD+GAE groups compared with the HD group, indicating that GAE supplementation was effective in reducing the expressions of these genes. Among the GAE supplemented groups, the levels of SREBP-1c, PPARγ, C/EBPα in HD+GAE group were significantly lower than those in HD+GAE1, HD+GAE2 and HD+CLA groups. Kang et al. [18] reported GAE inhibits adipocyte differentiation and lipid accumulation in 3T3-L1 adipocytes. Furthermore, it has been also reported that polyphenolic compounds in natural products may regulate signaling pathways that involve PPARγ, C/EBPα, and SREBP-1c [43]. Plant-derived polyphenols such as flavonoids exert their anti-obesity effects by interacting with fat mass and obesity-associated genes [44]. Seaweeds are also known to be a rich source of phenolic compounds with various important biological activities such as phlorotannins. It was recently reported that treatment with phlorotannins results in decreased adipogenesis and decreased lipogenesis in 3T3-L1 preadipocytes [45]. The GAE in this study was analyzed to contain polyphenols and flavonoids. These compound classes may therefore be responsible for the anti-obesity effect of GAE observed in this study, suggesting that GAE contains relatively enriched anti-obesity polyphenol compounds. Based on these results, the reduction of adipogenesis-related gene expression in HD+GAE group mice may be also attributed to polyphenols and flavonoids contained in GAE.

A major role of AMPK is to regulate the lipid biosynthesis pathway and energy metabolism in adipocytes [46] Its activation suppresses the expression of PPARγ and FAS during adipogenesis [47] Furthermore, AMPK stimulates mitochondrial fatty acid oxidation and adipocyte lipolysis [48]. It is also activated by adiponectin, which provides the mechanistic link between adiponectin levels and fatty acid oxidation [47]. The expression of HSL is maintained in the face of AMPK activation in the adipose tissue [49]. It is a key lipase that degrades triglycerides by splitting the ester bonds, thus controlling the lipolysis pathway in adipose tissue [50]. This study showed that pAMPK and HSL expressions in the HD+GAE groups were significantly higher than those in the HD group. These results indicate that GAE inhibits hepatic lipid accumulation through the activation of AMPK, thereby suppressing the lipogenic enzymes and increasing hepatic fatty acid oxidation. In addition, GAE elevated HSL expression and decreased lipid accumulation by stimulating lipolysis. Among the GAE supplemented groups, HD+GAE3 group showed the highest levels in pAMPK and HSL expressions. Especially, the level of HSL in HD+GAE3 group was significantly higher than that in HD+CLA group. Polyphenols such as flavonoids have been reported to inhibit adipocyte differentiation by activating AMPK [51], and may therefore be responsible for the anti-obesity effects of GAE observed in this study.

In conclusion, this study demonstrated that GAE ameliorates obesity in diet-induced obese mice.
obesity by inhibiting adipogenesis in HD-fed obese mice. The results showed that GAE supplementation significantly decreased body weight gain, adipose tissue mass, leptin concentration, and the levels of TG and TC in the plasma and liver. Furthermore, GAE was also shown to decrease the expression levels of the adipogenic transcription factors SREBP-1c, FAS, PPARγ, and C/EBPα, and increase pAMPK expression. Therefore, GAE has the potential to be developed as a source of anti-obesity therapeutic agents.

CONFLICT OF INTEREST

The authors declare no potential conflicts of interests.

REFERENCES

1. Nieves JW, Komar L, Cosman F, Lindsay R. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr 1998;67:18-24.
2. Kopelman PG. Obesity as a medical problem. Nature 2000;404:635-43.
3. Wang T, Wang Y, Kontani Y, Kobayashi Y, Sato Y, Mori N, Yamashita H. Evodiamine improves induced obesity in a uncoupling protein-1-independent manner: involvement of antiadipogenic mechanism and extracellularly regulated kinase/mitogen-activated protein kinase signaling. Endocrinology 2008;149:358-66.
4. Choi H, Eo H, Park K, Jin M, Park EJ, Kim SH, Park JE, Kim S. A water-soluble extract from Cucurbita moschata shows anti-obesity effects by controlling lipid metabolism in a high fat diet-induced obesity mouse model. Biochem Biophys Res Commun 2007;359:419-25.
5. Giri S, Rattan R, Haq E, Khan M, Yasin R, Won JS, Key L, Singh AK, Singh I. AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model. Nutr Metab (Lond) 2006;3:31.
6. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev 2000;14:1293-307.
7. Sztalryd C, Kraemer FB. Regulation of hormone-sensitive lipase in streptozotocin-induced diabetic rats. Metabolism 1995;44:1391-6.
8. Lefterova MI, Lazar MA. New developments in adipogenesis. Trends Endocrinol Metab 2009;20:107-14.
9. Wasan KM, Looije NA. Emerging pharmacological approaches to the treatment of obesity. J Pharm Pharm Sci 2005;8:259-71.
10. Lee YS, Cha BY, Saito K, Choi SS, Wang XX, Choi BK, Yonezawa H. Evodiamine improves induced obesity in a uncoupling protein-1-independent manner: involvement of antiadipogenic mechanism and extracellularly regulated kinase/mitogen-activated protein kinase signaling. Endocrinology 2008;149:358-66.
11. Hofbauer KG, Nicholson JR. Pharmacotherapy of obesity. Exp Clin Endocrinol Diabetes 2006;114:475-84.
12. Bray GA. Medical therapy for obesity. Mt Sinai J Med 2010;77:407-17.
13. Choi KM, Lee YS, Shin DM, Lee S, Yoo KS, Lee MK, Lee JH, Kim SY, Lee YM, Hong JT, Yun YP, Yoo HS. Green tomato extract attenuates high-fat-diet-induced obesity through activation of the AMPK pathway in CS7BL/6 mice. J Nutr Biochem 2013;24:335-42.
14. Kadam SU, Prabhansankar P. Marine foods as functional ingredients in bakery and pasta products. Food Res Int 2010;43:1975-80.
15. Yan X, Nagata T, Fan X. Antioxidative activities in some common seaweeds. Plant Foods Hum Nutr 1998;52:253-62.
(Athens) 2005;4:189-99.
30. Staiger H, Tsirvint O, Machan J, Thamer C, Fritsche A, Maerker E, Schick F, Häring HU, Stumvoll M. Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 2003;11:368-72.
31. Jequier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002;967:379-88.
32. Lee Y, Wang MY, Kakuma T, Wang ZW, Babcock E, McCorkle K, Higa M, Zhou YT, Unger RH. Liporegulation in diet-induced obesity: The antisteatotic role of hyperleptinemia. J Biol Chem 2001;276:5629-35.
33. Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 2003;52:1355-63.
34. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-703.
35. Siegrist M, Rank M, Wolfarth B, Langhof H, Haller B, Koenig W, Halle M. Leptin, adiponectin, and short-term and long-term weight loss after a lifestyle intervention in obese children. Nutrition 2013;29:851-7.
36. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003;285:E527-33.
37. Park J, Rho HK, Kim KH, Choe SS, Lee YS, Kim JB. Overexpression of glucose-6-phosphate dehydrogenase is associated with lipid dysregulation and insulin resistance in obesity. Mol Cell Biol 2005;25:S146-57.
38. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996;1302:93-109.
39. Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, Spiegelman BM. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev 2002;16:22-6.
40. Kamei R, Kitagawa Y, Kadokura M, Hattori F, Hazeki O, Ebina Y, Nishihara T, Oikawa S. Shikonin stimulates glucose uptake in 3T3-L1 adipocytes via an insulin-independent tyrosine kinase pathway. Biochem Biophys Res Commun 2002;292:642-51.
41. Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci U S A 1998;95:4333-7.
42. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-61.
43. Wang S, Moustaïd-Moussa N, Chen L, Mo H, Shastri A, Su R, Bapat P, Kwon I, Shen CL. Novel insights of dietary polyphenols and obesity. J Nutr Biochem 2014;25:1-18.
44. Mohammed A, Al-Numair KS, Balakrishnan A. Docking studies on the interaction of flavonoids with fat mass and obesity associated protein. Pak J Pharm Sci 2015;28:1647-53.
45. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009;9:407-16.
46. Jung HA, Jung HJ, Jeong HY, Kwon HJ, Ali MY, Choi JS. Phlorotannins isolated from the edible brown alga Ecklonia stolonifera exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating C/EBP alpha and PPAR gamma. Fitoterapia 2014;92:260-9.
47. Vingtdeux V, Chandakkar P, Zhao H, Davies P, Marambaud P. Small-molecule activators of AMP-activated protein kinase (AMPK), RSV431 and RSV445, inhibit adipogenesis. Mol Med 2011;17:1022-30.
48. Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes 2008;32 Suppl 4:S7-12.
49. Watt MJ, Holmes AG, Pinnamaneni SK, Garnham AP, Steinberg GR, Kemp BE, Febbraio MA. Regulation of HSL serine phosphorylation in skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab 2006;290:E500-8.
50. Bezairie V, Mairal A, Ribet C, Lefort C, Girousse A, Jocken J, Laurenciexine J, Anesia R, Rodriguez AM, Ryden M, Stenson BM, Dani C, Alilaud G, Arner P, Langin D. Contribution of adipose triglyceride lipase and hormone-sensitive lipase to lipolysis in hMADS adipocytes. J Biol Chem 2009;284:18282-91.
51. Son Y, Nam JS, Jang MK, Jung IA, Cho SL, Jung MH. Antiobesity activity of Vigna nakashimae extract in high-fat diet-induced obesity. Biosci Biotechnol Biochem 2013;77:332-8.